Last reviewed · How we verify
Transcutaneous mode of administration
Transcutaneous mode of administration is a Biologic drug developed by Objectif Recherche Vaccins SIDA. It is currently in Phase 1 development.
At a glance
| Generic name | Transcutaneous mode of administration |
|---|---|
| Sponsor | Objectif Recherche Vaccins SIDA |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Investigating the Tolerability and Feasibility of tVNS Following aSAH (NA)
- Effect of Acupuncture on Psychoneurological Symptom Cluster in Breast Cancer Survivors (NA)
- Transcutaneous Electrical Acustimulation for IBS-D: A Multicenter Study (NA)
- Comparison of the Effect of Genicular Nerve Block and Physical Therapy in Patients With Knee Osteoarthritis (NA)
- Pain Neuroscience Education in Myofascial Pain Syndrome (NA)
- Immediate and 1-week Efficacy of a Single Session of Sciatic Nerve Electrical Stimulation in the Management of Low-back Related Leg Pain (NA)
- Sustained Natural Apophyseal Glides With and Without Integrated Neuromuscular Inhibition Technique in Neck Pain (NA)
- Efficacy of Sciatic Nerve Electrical Stimulation and Therapeutic Exercise in the Management of Low-back Related Leg Pain (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Transcutaneous mode of administration CI brief — competitive landscape report
- Transcutaneous mode of administration updates RSS · CI watch RSS
- Objectif Recherche Vaccins SIDA portfolio CI
Frequently asked questions about Transcutaneous mode of administration
What is Transcutaneous mode of administration?
Transcutaneous mode of administration is a Biologic drug developed by Objectif Recherche Vaccins SIDA.
Who makes Transcutaneous mode of administration?
Transcutaneous mode of administration is developed by Objectif Recherche Vaccins SIDA (see full Objectif Recherche Vaccins SIDA pipeline at /company/objectif-recherche-vaccins-sida).
What development phase is Transcutaneous mode of administration in?
Transcutaneous mode of administration is in Phase 1.